CRS3123
Phase 2Small molecule
CRS3123 is one of 14 small molecule programs targeting Clostridioides difficile Infection. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Clostridioides Difficile Infection
#DrugCompanyPhaseTrials
1Active Comparator
ModernaPhase 2
RBX2660
FerringPhase 3
VE303
VVedanta Biosciences, Inc.
Phase 3
MBK-01
MMikrobiomik Healthcare Company S.L.
Phase 3
Vancomycin or Fidaxomicin
SSejtterapia Kozpont Kft.
Phase 3
Dificlir
Merck & Co.Preclinical
EXL01
EExeliom Biosciences
Phase 2
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
AZD5148
AstraZenecaPhase 2
ZINPLAVA
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Trial1 trial
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02106338·36 enrolled
Single Dose1 trial
Phase I Trial of a Single Dose of CRS3123
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01551004·40 enrolled
Clostridioides difficile Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CRS3123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details